Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer.
Checkpoint blockade
clinical trial
colorectal cancer
immunogenic cell death
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
21
9
2023
pubmed:
20
9
2023
entrez:
20
9
2023
Statut:
epublish
Résumé
Checkpoint blockade immunotherapy transforms many types of cancer; however, in the field of metastatic colorectal cancer, checkpoint blockers are only effective in microsatellite-unstable tumors, which represent only a minority of patients. Microsatellite-stable tumors are thought to be immunoresistant. A recent publication demonstrates that, contrary to the standard view point, the combination of chemo-immunotherapy could trigger a tumor-specific immune response, leading to clinical benefit.
Identifiants
pubmed: 37727739
doi: 10.1080/2162402X.2023.2257098
pii: 2257098
pmc: PMC10506430
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2257098Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the author(s).
Références
JAMA Oncol. 2020 Jun 1;6(6):831-838
pubmed: 32379280
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Front Immunol. 2019 Aug 06;10:1816
pubmed: 31447840
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
Cancer Res. 2010 Apr 15;70(8):3052-61
pubmed: 20388795
Nat Immunol. 2022 Apr;23(4):487-500
pubmed: 35145297
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
Nat Med. 2023 Aug;29(8):2087-2098
pubmed: 37563240